WO2013171048A1 - Bis azainositol heavy metal complexes for x-ray imaging - Google Patents
Bis azainositol heavy metal complexes for x-ray imaging Download PDFInfo
- Publication number
- WO2013171048A1 WO2013171048A1 PCT/EP2013/058590 EP2013058590W WO2013171048A1 WO 2013171048 A1 WO2013171048 A1 WO 2013171048A1 EP 2013058590 W EP2013058590 W EP 2013058590W WO 2013171048 A1 WO2013171048 A1 WO 2013171048A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carboxy
- amino
- methyl
- ethyl
- triolate
- Prior art date
Links
- 229910001385 heavy metal Inorganic materials 0.000 title claims abstract description 22
- 238000003384 imaging method Methods 0.000 title description 5
- 239000003446 ligand Substances 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 136
- 150000001875 compounds Chemical class 0.000 claims description 85
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 59
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 claims description 38
- 229910052751 metal Inorganic materials 0.000 claims description 34
- 239000000203 mixture Substances 0.000 claims description 34
- 239000002184 metal Substances 0.000 claims description 33
- 229910052735 hafnium Inorganic materials 0.000 claims description 30
- VBJZVLUMGGDVMO-UHFFFAOYSA-N hafnium atom Chemical compound [Hf] VBJZVLUMGGDVMO-UHFFFAOYSA-N 0.000 claims description 30
- 229910052765 Lutetium Inorganic materials 0.000 claims description 18
- OHSVLFRHMCKCQY-UHFFFAOYSA-N lutetium atom Chemical compound [Lu] OHSVLFRHMCKCQY-UHFFFAOYSA-N 0.000 claims description 18
- 229910052691 Erbium Inorganic materials 0.000 claims description 16
- UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical group [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 claims description 16
- 239000000032 diagnostic agent Substances 0.000 claims description 15
- 229940039227 diagnostic agent Drugs 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 15
- 239000007864 aqueous solution Substances 0.000 claims description 12
- 150000004677 hydrates Chemical class 0.000 claims description 12
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 11
- 229910052688 Gadolinium Inorganic materials 0.000 claims description 10
- 229910052769 Ytterbium Inorganic materials 0.000 claims description 10
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical group [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims description 10
- NAWDYIZEMPQZHO-UHFFFAOYSA-N ytterbium Chemical compound [Yb] NAWDYIZEMPQZHO-UHFFFAOYSA-N 0.000 claims description 10
- 229910052689 Holmium Inorganic materials 0.000 claims description 9
- KJZYNXUDTRRSPN-UHFFFAOYSA-N holmium atom Chemical group [Ho] KJZYNXUDTRRSPN-UHFFFAOYSA-N 0.000 claims description 9
- 229910052771 Terbium Inorganic materials 0.000 claims description 6
- 229910052775 Thulium Inorganic materials 0.000 claims description 6
- 229910052797 bismuth Inorganic materials 0.000 claims description 6
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical group [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 claims description 6
- 229910052692 Dysprosium Inorganic materials 0.000 claims description 5
- KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical group [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- 229910052684 Cerium Inorganic materials 0.000 claims description 4
- 229910052693 Europium Inorganic materials 0.000 claims description 4
- 229910052779 Neodymium Inorganic materials 0.000 claims description 4
- 229910052777 Praseodymium Inorganic materials 0.000 claims description 4
- 229910052772 Samarium Inorganic materials 0.000 claims description 4
- ZMIGMASIKSOYAM-UHFFFAOYSA-N cerium Chemical group [Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce] ZMIGMASIKSOYAM-UHFFFAOYSA-N 0.000 claims description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical group [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 claims description 4
- 229910052746 lanthanum Inorganic materials 0.000 claims description 4
- FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical group [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 claims description 4
- QEFYFXOXNSNQGX-UHFFFAOYSA-N neodymium atom Chemical group [Nd] QEFYFXOXNSNQGX-UHFFFAOYSA-N 0.000 claims description 4
- PUDIUYLPXJFUGB-UHFFFAOYSA-N praseodymium atom Chemical group [Pr] PUDIUYLPXJFUGB-UHFFFAOYSA-N 0.000 claims description 4
- KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical group [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 claims description 4
- 150000003628 tricarboxylic acids Chemical class 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 2
- 150000001735 carboxylic acids Chemical class 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 239000002872 contrast media Substances 0.000 abstract description 23
- 150000003627 tricarboxylic acid derivatives Chemical class 0.000 abstract 1
- 239000011734 sodium Substances 0.000 description 71
- 229910001868 water Inorganic materials 0.000 description 53
- 239000013078 crystal Substances 0.000 description 46
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 39
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 33
- 239000000243 solution Substances 0.000 description 29
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 22
- 239000007787 solid Substances 0.000 description 20
- 101100425947 Mus musculus Tnfrsf13b gene Proteins 0.000 description 18
- 229940068911 chloride hexahydrate Drugs 0.000 description 18
- 238000002591 computed tomography Methods 0.000 description 18
- VOAPTKOANCCNFV-UHFFFAOYSA-N hexahydrate;hydrochloride Chemical compound O.O.O.O.O.O.Cl VOAPTKOANCCNFV-UHFFFAOYSA-N 0.000 description 18
- 238000010521 absorption reaction Methods 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 15
- 229910052747 lanthanoid Inorganic materials 0.000 description 15
- 150000002602 lanthanoids Chemical class 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 14
- 238000006073 displacement reaction Methods 0.000 description 14
- 238000000524 positive electrospray ionisation mass spectrometry Methods 0.000 description 14
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 13
- 238000005160 1H NMR spectroscopy Methods 0.000 description 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 13
- 239000007858 starting material Substances 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- 238000005481 NMR spectroscopy Methods 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 229910001415 sodium ion Inorganic materials 0.000 description 8
- 238000001704 evaporation Methods 0.000 description 7
- 230000008020 evaporation Effects 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 230000005540 biological transmission Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000012937 correction Methods 0.000 description 6
- 238000013480 data collection Methods 0.000 description 6
- 238000002354 inductively-coupled plasma atomic emission spectroscopy Methods 0.000 description 6
- 239000011630 iodine Substances 0.000 description 6
- 229960002358 iodine Drugs 0.000 description 6
- 229910052740 iodine Inorganic materials 0.000 description 6
- 235000013675 iodine Nutrition 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 238000001095 inductively coupled plasma mass spectrometry Methods 0.000 description 5
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 125000004430 oxygen atom Chemical group O* 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- -1 among others Chemical class 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 210000005242 cardiac chamber Anatomy 0.000 description 4
- PDPJQWYGJJBYLF-UHFFFAOYSA-J hafnium tetrachloride Chemical compound Cl[Hf](Cl)(Cl)Cl PDPJQWYGJJBYLF-UHFFFAOYSA-J 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 229920001429 chelating resin Polymers 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000002059 diagnostic imaging Methods 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 229960000367 inositol Drugs 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 229960000281 trometamol Drugs 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 0 COC(C*N)=O Chemical compound COC(C*N)=O 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 101150061135 TBCA gene Proteins 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000005277 cation exchange chromatography Methods 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940039231 contrast media Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000008098 formaldehyde solution Substances 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- 229960002163 hydrogen peroxide Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011895 specific detection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 1
- BMVXCPBXGZKUPN-UHFFFAOYSA-N 1-hexanamine Chemical compound CCCCCCN BMVXCPBXGZKUPN-UHFFFAOYSA-N 0.000 description 1
- 238000004009 13C{1H}-NMR spectroscopy Methods 0.000 description 1
- 125000006290 2-hydroxybenzyl group Chemical group [H]OC1=C(C([H])=C([H])C([H])=C1[H])C([H])([H])* 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 101100352755 Drosophila melanogaster pnt gene Proteins 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- HEMHJVSKTPXQMS-DYCDLGHISA-M Sodium hydroxide-d Chemical compound [Na+].[2H][O-] HEMHJVSKTPXQMS-DYCDLGHISA-M 0.000 description 1
- 238000000333 X-ray scattering Methods 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000013170 computed tomography imaging Methods 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 150000001934 cyclohexanes Chemical class 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000005292 diamagnetic effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- ARRNBPCNZJXHRJ-UHFFFAOYSA-M hydron;tetrabutylazanium;phosphate Chemical compound OP(O)([O-])=O.CCCC[N+](CCCC)(CCCC)CCCC ARRNBPCNZJXHRJ-UHFFFAOYSA-M 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000008155 medical solution Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000010244 region-of-interest analysis Methods 0.000 description 1
- 229920003987 resole Polymers 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical class [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 238000004467 single crystal X-ray diffraction Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- QVSRWXFOZLIWJS-UHFFFAOYSA-N trimethylsilyl propanoate Chemical compound CCC(=O)O[Si](C)(C)C QVSRWXFOZLIWJS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/003—Compounds containing elements of Groups 4 or 14 of the Periodic Table without C-Metal linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
Definitions
- the present invention describes a new class of bis azainositol heavy metal complexes, especially trinuclear heavy metal complexes comprising two hexadentate azainositol tri- carboxylic acid ligands, a method for their preparation and their use as X-ray contrast agents.
- pM -log[M]f re e
- a high kinetic stability can additionally avoid the dissociation of metal complexes and thereby improve the in vivo safety. Chapon et al. (J. All. Comp.
- AII-c/s-1 ,3,5-triamino-2,4,6-cyclohexane triol derivatives, their use and methods for their preparation were also described by Laboratorien Hausmann AG in EP, A, 190 676.
- Byk Gulden Lomberg Chemische Fabrik GmbH described taci based transition metal complexes for magnetic resonance diagnostics in WO 91/10454.
- Nycomed AS in WO 90/08138 described heterocyclic chelating agents for the preparation of diagnostic and therapeutic agents for magnetic resonance imaging, scintigraphy, ultrasound imaging, radiotherapy and heavy metal detoxification.
- the formation of trinuclear iron 1 " complexes was suggested by G. Welti ⁇ Dissertation, Zurich 1998) for an acetate and by A. Egli ⁇ Dissertation, Zurich 1994) for a 2- hydroxybenzyl derivative of taci.
- G. Welti also described the synthesis of henium v and Rhenium VH complexes of acetate derived ligands based on taci with a Mil_i stoichiometry.
- Hafnium and lanthanides are characterized by a higher absorption coefficient for X-rays than iodine, especially in the range of tube voltages normally used in modern CT.
- a modern CT X-ray-tube requires a minimum voltage of about 70 kV and reaches maximum voltage of 160 kV.
- iod ine general ly does not provide ideal attenuation features for this technology.
- the attenuation optimum (k-edge) of hafnium and lanthanides corresponds better to the ranges of voltages used in CT. Therefore the new hafnium and lanthanides complexes require a similar or lower contrast media dosage than conventional triiodinated contrast agents.
- hafnium and lanthanides based contrast agents will allow more flexibility for CT scanning protocols and lead to scan protocols that provide equivalent diagnostic value at lower radiation doses. Especially this feature is of high importance for CT.
- tech n ical development goals i n terms of spatia l and tem poral resol ution h ave approached the limit of clinical significance, reduction of the radiation burden of CT scanning has today become a central aspect of the development of new CT scanners and X-ray machines.
- ALARA-rule radiation exposure has to be reduced to levels: As Low As Reasonably Achievable
- the new hafnium and lanthanides based contrast agents will contribute to high-quality diagnostic imaging at reduced radiation exposure.
- the state of the art described above consists of either physiologically stable heavy metal complexes with a low metal content per molecule or complexes with a high metal content, which are not thermodynamically stable enough for a physiological application or hold a metal that is not suitable for a diagnostic X-ray CT application.
- the aim of the present invention was to provide sufficiently stable, water soluble and well tolerated hafnium and lanthanide complexes with a higher metal content for use as X-ray contrast agents in diagnostic imaging, especially in modern computed tomography.
- the compounds of the present invention are excreted fast and quantitatively via the kidneys, comparable to the well established triiodinated X-ray contrast agents.
- the invention of suitable new bis-azainositol heavy metal complexes enables for the first time the practical use of this compound class as X-ray contrast agents in diagnostic imaging.
- the present invention is directed to bis azainositol heavy metal complexes, especially trinuclear heavy metal complexes comprising two hexadentate azainositol tricarboxylic acid ligands.
- the invention is directed to compounds of the general formula (I),
- R 1 , R 2 and R 3 are independently selected from H or methyl; n is 1 or 2; x is 3 or 4; and y is 0 or 3; with the proviso that (3 times x) + y is 12; including any protonated species and any deprotonated species of said compou nds, including all isomeric forms of said compounds, including but not limited to enantiomers, diastereomers, regioisomers and mixtures thereof, and any pharmaceutically acceptable salt of such compounds or hydrates thereof.
- the invention relates to compounds of formula (I), supra, wherein M is Gadolinium, Terbium, Dysprosium, Holmium, Erbium, Thulium, Ytterbium, Lutetium, Hafnium or Bismuth.
- the invention relates to compounds of formula (I), supra, wherein M is Hafnium (Hf).
- the invention relates to compounds of formu la (I), supra, wherein R 1 , R 2 and R 3 are methyl. It is to be understood that the present invention relates also to any combination of the preferred embodiments described above.
- the invention relates to com pounds of formula (I), supra, wherein M is Hafnium (Hf), and R 1 , R 2 and R 3 are methyl.
- Trinuclear complexes of the general formula (I), which are charged at physiological pH can be neutralized by addition of suitable, physiologically biocompatible counter ions, e.g. sodium ions or suitable cations of organic bases including, among others, those of primary, secondary or tertiary amines, for example /V-methylglucamine.
- suitable, physiologically biocompatible counter ions e.g. sodium ions or suitable cations of organic bases including, among others, those of primary, secondary or tertiary amines, for example /V-methylglucamine.
- Lysine, arginine or ornithine are suitable cations of amino acids, as generally are those of other basic naturally occurring amino acids.
- a3[Lu3(H-3tacita)2] Trisodium bis ⁇ 3-[(all-c/s)-2- ⁇ [(carboxy-l O)methyl]amino-1 4- ⁇ [(carboxy-2KO)methyl]amino-2KA/ ⁇ -6- ⁇ [(carboxy-3 O)methy!]amino-3 A/ ⁇ cyclo- hexane-1 ,3,5-triolate-1 ⁇ 2 0 ⁇ 0 3 : 2 ⁇ 2 0 3 ,0 5 : 3 ⁇ 2 O , 0 ] ⁇ tri I u tetate( 111 )
- Na3[Gd3(H.3tacita)2] Trisodium bis ⁇ 3-[(all-c/s)-2- ⁇ [(carboxy-l O)methyl]amino-1 4- ⁇ [(carboxy-2KO)methyl]amino-2KA/ ⁇ -6- ⁇ [(carboxy-3KO)methyl]amino-3K/ ⁇ / ⁇ cyclo- hexane-1 ,3,5-triolate-1 ⁇ 2 0 ⁇ 0 3 : 2 ⁇ 2 0 3 ,0 5 : 3K 2 0 1 ,0 5 ] ⁇ trigadolinate(lll)
- Na3[Ho3(H-3tacita)2] Trisodium bis ⁇ 3-[(all-c s)-2- ⁇ [(carboxy-l O)methyl]amino-1 4- ⁇ [(carboxy-2KO)methyl]amino-2K/V ⁇ -6- ⁇ [(carboxy-3KO)methyl]amino-3KA/ ⁇ cyclo- hexane-1 ,3,5-triolate-l ⁇ 2 0 ⁇ 0 3 : 2 ⁇ 2 0 3 ,0 5 : 3K 2 0 1 ,0 5 ] ⁇ triholmate(lll)
- Na3[Er3(H-3tacita)2] Trisodium bis ⁇ p3-[(all-c/s)-2- ⁇ [(carboxy-1 KO)methyl]amino-1 K/V ⁇ - 4- ⁇ [(carboxy-2KO)methyl]amino-2KA/ ⁇ -6- ⁇ [(carboxy-3KO)methyl]amino-3K/ ⁇ / ⁇ cyclo- hexane-1 ,3,5-triolate-l ⁇ 2 0 ⁇ 0 3 : 2 ⁇ 2 0 3 ,0 5 : 3K 2 0 1 ,0 5 ] ⁇ trierbate(lll)
- Na3[Yb3(H-3tacita)2] Trisodium bis ⁇ 3-[(all-c/s)-2- ⁇ [(carboxy-1 KO)methyl]amino-1 ⁇ / ⁇ - 4- ⁇ [(carboxy-2KO)methyl]amino-2K/ ⁇ / ⁇ -6- ⁇ [(carboxy-3KO)methyl]amino-3KA/ ⁇ cyclo- hexane-1 ,3,5-triolate-1 ⁇ 2 0 ⁇ 0 3 : 2 ⁇ 2 0 3 , 0 5 : 3K 2 0 1 ,0 5 ] ⁇ triytterbate(lll)
- [Hf3(H-3macita)2] Bis ⁇ 3-[(all-c/s)-2- ⁇ [(carboxy-1 KO)methyl](methyl)amino-1 ⁇ -4- ⁇ [(carboxy-2KO)methyl](methyl)amino-2K/ ⁇ / ⁇ -6- ⁇ [(carboxy-3KO)methyl](methyl)amino- 3K/V ⁇ cyclohexane-1 ,3,5-triolate-l
- Na3[i-U3(H-3macita)2] Trisodium bis ⁇ 3-[(all-c s)-2- ⁇ [(carboxy-l O)methyl](methyl)- amino-l KA/ ⁇ -4- ⁇ [(carboxy-2KO)methyl](methyl)amino-2K/ ⁇ / ⁇ -6- ⁇ [(carboxy-3KO)methyl]- (methyl)amino-3K/V ⁇ cyclohexane-1 ,3,5-triolate-l ⁇ 2 0 1 , 0 3 : 2 ⁇ 2 0 3 ,0 5 :
- Na.3[Gd3(H-3macita)2] Trisodium bis ⁇ 3-[(all-cs)-2- ⁇ [(carboxy-lKO)methyl](methyl)- amino-lK/V ⁇ -4- ⁇ [(carboxy-2KO)methyl](methyl)amino-2KA/ ⁇ -6- ⁇ [(carboxy-3KO)methyl]- (methyl)amino-3 A/ ⁇ cyclohexane-1 ,3,5-triolate-1 2 0 1 ,0 3 : 2 ⁇ 2 0 3 ,0 5 :
- Na3[Ho3(H-3macita)2] Trisodium bis ⁇ 3-[(all-cs)-2- ⁇ [(carboxy-l O)methyl](methyl)- amino-l A/ ⁇ -4- ⁇ [(carboxy-2 O)methyl](methyl)amino-2KA/ ⁇ -6- ⁇ [(carboxy-3 O)methyl]- (methyl)amino-3K/V ⁇ cyclohexane-1 ,3,5-triolate-1 ⁇ 2 0 1 ,0 3 : 2 2 0 3 ,0 5 :
- Na3[Er3(H-3macita)2] Trisodium bis ⁇ 3-[(all-c/s)-2- ⁇ [(carboxy-l O)methyl](methyl)- amino-l KA/ ⁇ -4- ⁇ [(carboxy-2KO)methyl](methyl)amino-2KA/ ⁇ -6- ⁇ [(carboxy-3KO)methyl]- (methyl)amino-3K/V ⁇ cyclohexane-1 ,3,5-triolate-1 ⁇ 2 0 1 ,0 3 : 2 2 0 3 ,0 5 :
- a3[Yb3(H-3macita)2] Trisodium bis ⁇ 3-[(all-c/s)-2- ⁇ [(carboxy-l KO)methyl](methyl)- amino-l K/V ⁇ -4- ⁇ [(carboxy-2KO)methyl](methyl)amino-2KA/ ⁇ -6- ⁇ [(carboxy-3KO)methyl]- (methyl)amino-3K/V ⁇ cyclohexane-1 ,3,5-triolate-1 ⁇ 2 0 1 ,0 3 : 2 ⁇ 2 0 3 ,0 5 :
- Na3[Lu3(H-3tacitp)2] Trisodium bis ⁇ 3-[(all-c/s)-2- ⁇ [(carboxy-1 KO)ethyl]amino-1 ⁇ / ⁇ -4- ⁇ [(carboxy-2KO)ethyl]amino-2K/V ⁇ -6- ⁇ [(carboxy-3KO)ethyl]amino-3K ⁇ / ⁇ cyclohexane- 1 ,3,5-triolate-1 ⁇ 2 0 1 ,0 3 : 2 ⁇ 2 0 3 ,0 5 : 3K 2 0 1 ,0 5 ] ⁇ trilutetate(lll)
- Na3[Ho3(H-3tacitp)2] Trisodium bis ⁇ 3-[(all-c/s)-2- ⁇ [(carboxy-1 KO)ethyl]amino-1 ⁇ / ⁇ -4- ⁇ [(carboxy-2KO)ethyl]amino-2K/V ⁇ -6- ⁇ [(carboxy-3KO)ethyl]amino-3KA/ ⁇ cyclohexane- 1 ,3,5-triolate-l K 2 0 1 , 0 3 : 2 2 0 3 ,0 5 : 3K 2 0 1 ,0 5 ] ⁇ triholmate(lll)
- Na3[Er3(H.3tacitp)2] Trisodium bis ⁇ 3-[(all-c/s)-2- ⁇ [(carboxy-1 KO)ethyl]amino-1 K/V ⁇ -4- ⁇ [(carboxy-2KO)ethyl]amino-2K/V ⁇ -6- ⁇ [(carboxy-3KO)ethyl]amino-3KA/ ⁇ cyclohexane- 1 ,3,5-triolate-l ⁇ 2 0 ⁇ 0 3 : 2 ⁇ 2 0 3 ,0 5 : 3K 2 0 1 , 0 5 ] ⁇ trierbate(lll)
- Na3[Yb3(H-3tacitp)2] Trisodium bis ⁇ 3-[(all-c/s)-2- ⁇ [(carboxy-1 KO)ethyl]amino-1 K V ⁇ -4- ⁇ [(carboxy-2KO)ethyl]amino-2K/V ⁇ -6- ⁇ [(carboxy-3KO)ethyl]amino-3KA/ ⁇ cyclohexane-
- [Hf 3 (H. 3 macitp)2] Bis ⁇ 3 -[(all-c/s)-2- ⁇ [(carboxy-1 KO)ethyl](methyl)amino-1 K/V ⁇ -4- ⁇ [(carboxy-2KO)ethyl](methyl)amino-2K/V ⁇ -6- ⁇ [(carboxy-3KO)ethyl](methyl)amino- 3KA/ ⁇ cyclohexane-1 ,3,5-triolate-1
- Na3[Lu3(H-3macitp)2] Trisodium bis ⁇ 3-[(all-c/s)-2- ⁇ [(carboxy-l KO)ethyl](methyl)- amino-l K/V ⁇ -4- ⁇ [(carboxy-2KO)ethyl](methyl)amino-2K/ ⁇ / ⁇ -6- ⁇ [(carboxy-3KO)ethyl]- (methyl)amino-3 /V ⁇ cyclohexane-1 ,3,5-triolate-1 ⁇ 2 0 1 ,0 3 : 2 ⁇ 2 0 3 ,0 5 : 3 ⁇ 2 0 1 ,0 5 ] ⁇ - lutetate(lll)
- Na3[Gd3(H-3macitp)2] Trisodium bis ⁇ 3-[(all-c/s)-2- ⁇ [(carboxy-l O)ethyl](methyl)- amino-l KA/ ⁇ -4- ⁇ [(carboxy-2KO)ethyl](methyl)amino-2K/V ⁇ -6- ⁇ [(carboxy-3KO)ethyl]- (methyl)amino-3K/V ⁇ cyclohexane-1 ,3,5-triolate-1
- Na3[Ho3(H-3macitp)2] Trisodium bis ⁇ 3-[(all-c/s)-2- ⁇ [(carboxy-l KO)ethyl](methyl)- amino-l K/V ⁇ -4- ⁇ [(carboxy-2 O)ethyl](methyl)amino-2KA/ ⁇ -6- ⁇ [(carboxy-3KO)ethyl]- (methyl)amino-3K/V ⁇ cyclohexane-1 ,3,5-triolate-1 ⁇ 2 0 1 ,0 3 : 2 ⁇ 2 0 3 ,0 5 : 3 ⁇ 2 0 1 ,0 5 ] ⁇ - holmate(lll)
- Na3[Er3(H-3macitp)2] Trisodium bis ⁇ 3-[(all-c/s)-2- ⁇ [(carboxy-l O)ethyl](methyl)- amino-l K/V ⁇ -4- ⁇ [(carboxy-2KO)ethyl](methyl)amino-2K ⁇ / ⁇ -6- ⁇ [(carboxy-3KO)ethyl]- (methyl)amino-3K/ ⁇ / ⁇ cyclohexane-1 ,3,5-triolate-1 ⁇ 2 0 1 ,0 3 : 2 ⁇ 2 0 3 ,0 5 : 3 ⁇ 2 0 ⁇ 0 5 ] ⁇ - erbate(lll)
- Na3[Yb3(H-3macitp)2] Trisodium bis ⁇ 3-[(all-c/ " s)-2- ⁇ [(carboxy-l KO)ethyl](methyl)- amino-l / ⁇ / ⁇ -4- ⁇ [(carboxy-2KO)ethyl](methyl)amino-2KA/ ⁇ -6- ⁇ [(carboxy-3KO)ethyl]- (methyl)amino-3K/v ⁇ cyclohexane-1 ,3,5-triolate-1 ⁇ 2 0 ⁇ 0 3 : 2 ⁇ 2 0 3 ,0 5 : 3 ⁇ 2 0 1 ,0 5 ] ⁇ - ytterbate(lll)
- the invention is directed to the process for the preparation of the compounds of the general formula (I).
- the invention is directed to the process for the preparation of the compounds of the general formula (I) from carboxylic acids of the general formula (II), wherein the substituents at the cyclo hexyl ring exhibit an all-c/s configuration;
- R 1 , R 2 and R 3 are independently H or methyl; and n is 1 or 2; and metal halogenides, wherein metal is Lanthanum, Cerium, Praseodymium, Neodymium, Samarium, Europium, Gadolinium, Terbium, Dysprosium, Holmium, Erbium, Thulium, Ytterbium, Lutetium, Hafnium or Bismuth; and halogenide is either chloride or bromide, and hydrates thereof, in aqueous solution under elevated temperatures ranging from 80°C to 1 60°C in a pH range of 1 to 6 preferably at 90° to 130°C in a pH range of 2 to 5.
- the invention is directed to compounds of general formula (I) for the manufacture of diagnostic agents, especially of X-ray diagnostic agents for administration to humans or animals.
- diagnostic agents for example the administration to human or animal subjects
- the compounds of general formula (I) will conveniently be formulated together with pharmaceutical carriers or excipient.
- the contrast media of the invention may conveniently contain pharmaceutical formulation aids, for example stabilizers, antioxidants, pH adjusting agents, flavors, and the like. They may be formulated for parenteral or enteral administration or for direct administration into body cavities.
- parenteral formulations contain a sterile solution or suspension in a concentration range from 150 to 600 mg metal/mL, especially 200 to 450 mg metal/mL of the new azainositol heavy metal complexes according to this invention.
- the media of the invention may be in conventional pharmaceutical formulations such as solutions, suspensions, dispersions, syrups, etc. in physiologically acceptable carrier media, preferably in water for injections.
- the contrast medium When the contrast medium is formulated for parenteral administration, it will be preferably isotonic or hypertonic and close to pH 7.4.
- Pharmaceutically acceptable salts of the compounds according to the invention also include salts of customary bases, such as, by way of example and by way of preference, alkali metal salts (for example sodium salts), alkaline earth metal salts (for example calcium salts) and ammonium salts, derived from ammonia or organic amines having 1 to 16 carbon atoms, such as, by way of example and by way of preference, /V-methylglucamine.
- customary bases such as, by way of example and by way of preference, alkali metal salts (for example sodium salts), alkaline earth metal salts (for example calcium salts) and ammonium salts, derived from ammonia or organic amines having 1 to 16 carbon atoms, such as, by way of example and by way of preference, /V-methylglucamine.
- the media of the invention should generally have a sufficiently high percentage of hafnium or late lanthanide, in particular a contrast medium with a high content of heavy metal per molecule.
- the present invention provides carboxylic acid derived ligands based on 1 ,3,5-triamino- 1 ,3,5-trideoxy-c/s-inositol (taci) that can readily form trinuclear, highly stable metal complexes with lanthanides and hafnium useful as X-ray contrast agents.
- taci 1 ,3,5-triamino- 1 ,3,5-trideoxy-c/s-inositol
- the ligand tacita was synthesized according to G. Welti ⁇ Dissertation, Zurich 1998) using the tri-O-benzylated taci derivative tbca as starting material which was alkylated in the reaction with the sterically demanding agents ⁇ /,/V-diisopropylethylamine and tert-butyl- bromoacetate (Scheme 1 ).
- the protecting groups were removed in boiling 6 M hydrochloric acid and pure h tacita was isolated by precipitation of the zwitterionic ligand at pH 5.5.
- New trinuclear heavy metal complexes of the aforementioned ligands with lanthanides and hafnium were synthesized by adding stoichiometric amounts of a corresponding metal salt to aqueous or methanolic solutions of the ligands (Scheme 3).
- the reaction mixtures were heated under alkaline (pH 8 - 9 / 1 - 2 h for lanthanide complexes) or acidic conditions (pH 2 - 3 / 20 h - 3 d for hafnium complexes). Isolation and purification of the desired complexes was obtained by conventional ion exchange chromatography, extraction, precipitation or ultrafiltration methods.
- the complexes were characterized by means of elemental analysis (C, H, N), mass spectrometry (ESI-MS) and IR spectroscopy.
- ESI-MS mass spectrometry
- IR spectroscopy IR spectroscopy.
- a metal analysis was performed by ICP-OES for selected compounds.
- the diamagnetic complexes with Lu 3 ' and Hf 4+ were furthermore examined by NMR spectroscopy revealing in each case th e form ation of two diastereomeric forms of the trinuclear complexes [M3(H-3L)2] 3" °: Solutions of the compounds always contain a mixture of the D3- and C2- symmetric isomer.
- chirai centres or other forms of isomeric centres are not otherwise defined in a compound according to the present invention, all forms of such stereoisomers, including enantiomers and diastereomers, are intended to be covered herein .
- Compounds containing chirai centres may be used as racemic mixture or as an enantiomerically enriched mixture or as a diastereomeric mixture or as a diastereomerically enriched mixture, or these isomeric mixtures may be separated using well-known techniques, and an individual stereoisomer maybe used alone.
- Figure 1 Time course of contrast enhancement after intravenously administration of Na 3 [Lu3(H. 3 tacita)2] (Example 2).
- Figure 2 Region analysis of left heart chamber and respective signal-change time curve after administration of a3[Lu3(H-3tacita)2] (Example 2).
- Figure 3 Crystal structure of of C2-[Lu3(H-3tacita)2] 3" (Example 2).
- the displacement ellipsoids are drawn at the 50 % probability level;
- H(-N) hydrogen atoms are shown as spheres of arbitrary size;
- H(-C) hydrogen atoms are omitted for clarity. Only one position is shown for the disordered oxygen atom 043.
- Fig ure 4 Crystal structure of C2-[Ho3(H-3tacita)2] 3" (Example 4). The displacement ellipsoids are drawn at the 50 % probability level; H(-N) hydrogen atoms are shown as spheres of arbitrary size; H(-C) hydrogen atoms are omitted for clarity.
- Fig u re 5 Crystal structure of D3-[Hf3(H-3tacitp)2] (Example 1 3). The displacement ellipsoids are drawn at the 30 % probability level; H(-N) hydrogen atoms are shown as spheres of arbitrary size; H(-C) hydrogen atoms are omitted for clarity. Only one position is shown for the disordered oxygen atom 065.
- Figure 6 Crystal structure of D3-[Ho3(H-3tacitp)2] 3" (Example 15).
- the displacement ellipsoids are drawn at the 50 % probability level;
- H(-N) hydrogen atoms are shown as spheres of arbitrary size;
- H(-C) hydrogen atoms are omitted for clarity. Only one position is shown for the disordered oxygen atom 026.
- Figure 7 Crystal structure of C2-[Lu3(H-3macitp)2] 3" (Example 1 9).
- the displacement ellipsoids are drawn at the 30 % probability level; H(-C) hydrogen atoms are omitted for clarity.
- Figure 8 Crystal structure of C2-[Er3(H-3macitp)2] 3" (Example 22). The displacement ellipsoids are drawn at the 30 % probability level; hydrogen atoms are omitted for clarity. Only one set of substituents is shown for the disordered groups bound to N2 and N4, respectively.
- the chemicals used for the synthetic work were of reagent grade quality and were used as obtained.
- Dowex 50 W-X2 (100-200 mesh, H* form) and Dowex 1 -X2 (50-100 mesh, CI " form) were from Sigma-Aldrich, the mixed bed ion exchange resin Amberlite MB-61 13 from Merck.
- the starting materials 1 ,3,5-triamino-1 ,3,5-trideoxy-c/s-inositol (taci) 1 and all- c/s-2,4,6-tris(benzyloxy)-1 ,3,5-cyclohexanetriamine (tbca) 2 were prepared as described in the literature.
- pH * of the D2O samples was adjusted using appropriate solutions of DCI and NaOD in D2O.
- pH * refers to the direct pH-meter reading (Metrohm 713 pH meter) of the D2O samples, using a Metrohm glass electrode with an aqueous (H2O) Ag/AgCI-reference that was calibrated with aqueous (H2O) buffer solutions.
- the program SQUEEZE of the PLATON package 4 was therefore applied and the electron density in the disordered regions was subtracted from the data sets.
- the final data sets contain the C 2 -[Lu 3 (H. 3 tacita) 2 ] 3" a n d th e C 2 -[Ho 3 (H. 3 tacita) 2 ] 3" anions and the C 2 -K 3 [Lu 3 (H. 3 macitp)2]-3H20 entity, respectively.
- the elemental formulae of the crystal structures were deduced from the amount of electrons that was subtracted in each case.
- H- 3 macitp2]-6.5H20 were located on a crystallographic mirror plane resulting in either case i n a 1 : 1 d isorder of two propionate penda nt arms an d two methyl g rou ps , respectively.
- Treatment of hydrogen atoms Calculated positions (riding model) were generally used for H(-C) atoms.
- the H(-N) positions of C2-K 3 [Lu 3 (H. 3 tacita)2]-20H2O and C2-K 3 [Ho 3 (H. 3 tacita)2]- 17.5H 2 0 were also calculated.
- H(-N) and H(-O) positions were refined using isotropic displacement parameters with Ui S0 of the H atoms being set to 1 .2 or 1 .5 x U eq of the pivotal N or O atom, respectively. Furthermore, restraints were used for the N-H and O-H distances. Not all of the H(-O) atoms of the solvent molecules in the crystal structures containing crystal water could be located and the corresponding positions were therefore not considered in the refinement.
- Mass spectra were measured on a Waters LC/MS spectrometer equipped with a ZQ 4000-ESI mass spectrometer (single quadrupol).
- the resulting solution was extracted twice with dichloromethane and the aqueous layer was evaporated to dryness.
- the white solid was dissolved in water (50 mL) and the pH was adjusted to 5.5 using sodium hydroxide (40 %) to get a white precipitate that was filtered off, washed with ethanol, and dried in vacuo.
- H.3tacita-3H20 (1 .8 g, 4.4 mmol) was suspended in water (200 mL) and the pH was adjusted to - 1 using concentrated hydrochloric acid. To the resulting solution was added a formaldehyde solution (37 %, 70 mL, 936 mmol) and platinum(IV) oxide (600 mg) as catalyst. The reaction mixture was hydrogenated in an autoclave at 5 atm H2. After 15 days, the catalyst was filtered off and the filtrate was concentrated to dryness. The residue was dissolved twice in a 1 : 1 mixture of water and formic acid (30 mL) and evaporated to dryness again. The remaining solid was taken up in few hydrochloric acid (0.5 M) and sorbed on DOWEX 50. The column was washed successively with water (1 L), 0.5 M hydrochloric acid (1 L), and 3 M hydrochloric acid (2 L). The 3 M fraction containing the product was evaporated to dryness and the light yellow solid was dried in vacuo.
- tacitpn (3.8 g, 10.7 mmol) was dissolved in sodium hydroxide (10.3 g of a 25 % solution, 64.4 mmol) and heated to reflux for 4 h. The solvent was removed and the residue was taken up in 1 hydrochloric acid (5 mL) and sorbed on DOWEX 50. The column was washed with water (1 L), 0.25 M hydrochloric acid (1 L), 1 M hydrochloric acid (1 L) and the product was eluted with 3 M hydrochloric acid (1 L). The solvent was removed and the solid dried in vacuo.
- H 3 tacitp-3HCI-3H20 400 mg, 0.7 mmol was dissolved in a formaldehyde solution (37 %, 25 mL, 334 mmol) and a small amount of Pd (10 %) / C was added.
- the reaction mixture was hydrogenated in an autoclave at 50 atm h1 ⁇ 2 for 4 days at RT.
- the reaction mixture was filtered off and the filtrate concentrated to dryness.
- the residue was dissolved twice in a 1 : 1 mixture of water and formic acid (30 mL) and evaporated to dryness again.
- the remaining solid was taken up in 3 hydrochloric acid (10 mL) and sorbed on DOWEX 50.
- Hafnium(IV) chloride (594 mg, 1 .9 mmol) was dissolved in water (20 mL). H3tacita-3H 2 0 (0.5 g, 1 .2 mmol) was added and the pH was adjusted to ⁇ 2.5 (1 M sodium hydroxide). The solution was heated to reflux for 20 h . The reaction mixture was filtered and the fi ltrate was sorbed on DOWEX 50 (H*-form). The product was eluted with water, the solvent removed and the white solid dried in vacuo.
- H3tacita-3H 2 0 (1 .0 g, 2.5 mmol) was suspended in methanol (120 mL).
- Sodium hydroxide (12.5 mL of a 1 M solution in methanol, 12.5 mmol) was added to get a clear solution to which were dropped 1 .5 eq of lutetium(lll) chloride hexahydrate (1 .5 g, 3.9 mmol) dissolved in methanol (20 mL).
- the suspension was heated to reflux for 2 h and reduced to a volume of 50 mL.
- the white solid was filtered off after cooling and dissolved in water (30 mL) at pH ⁇ 9 (adjusted with 1 M sodium hydroxide).
- the solution was heated to reflux again for 1 h, filtered and the product was precipitated from the filtrate after cooling with ethanol (150 mL).
- the white solid was filtered off and dried in vacuo.
- Atomic coordinates ( x 10 ⁇ ) and equivalent isotropic displacement parameters (A ⁇ x U(eq) is defined as one third of the trace of the orthogonalized U'J tensor.
- the complex was prepared from S-yacita-Sh O (220 mg, 0.5 mmol) and gadolinium(lll) chloride hexahydrate (280 mg, 0.8 mmol) by following the protocol for the preparation of the lutetium complex Na3[Lii3(H-3tacita)2].
- the complex was prepared according to the protocol for the lutetium complex a3[Lu3 (H-3tacita)2] using H3tacita-3H20 (150 mg, 0.4 mmol) and holmium(lll) chloride (146 mg, 0.5 mmol) as starting material.
- U(eq) is defined as one third of the trace of the orthogonalized U'J tensor.
- Figure 4 shows the crystal structure
- the complex was prepared according to the protocol for the lutetium complex Na3[Lu,3 (H-3tacita)2] using h tacita-Sh O (150 mg, 0.4 mmol) and erbium(lll) chloride hexahydrate (215 mg, 0.6 mmol) as starting material.
- Hafnium(IV) chloride (205 mg , 0.6 mmol) was dissolved in water (35 m!_).
- H3macita-3HCI-H20 250 mg, 0.5 mmol was added and the pH was adjusted to ⁇ 3 (1 M sodium hydroxide). The solution was heated to reflux for 24 h and allowed to stand at RT in an open beaker for one day afterwards. The solid was filtered off and dried in vacuo. Yield: 50 mg (14 %) [Hf3(H-3macita)2]-12H20 (C2-symmetric complex as major species).
- I R (cm "1 ): 51 8, 526, 538, 548, 557, 568, 582, 604, 626, 645, 675, 71 9, 766, 81 9, 839, 913, 928, 1004, 1031 , 1092, 1 129, 1 161 , 1206, 1260, 1319, 1348, 1449, 1475, 1 633, 2891 , 3439.
- H 3 macita-3HCI-H 2 0 150 mg, 0.3 mmol
- lutetium(lll) chloride hexahydrate 168 mg, 0.4 mmol
- water 30 mL
- Sodium hydroxide (1 M) was added to adjust the pH to ⁇ 8 and the clear solution was heated to refl ux for 2 h .
- the solvent was removed and the residue was treated with hot ethanol (20 mL).
- the insoluble salts were filtered off, the filtrate evaporated to dryness and the white solid dried in vacuo.
- the complex was prepared according to the protocol for the lutetium complex Na 3 [Lu 3 (H. 3 macita) 2 ] using H 3 macita-3HCI H 2 0 (150 mg, 0.3 mmol) and gadolinium(lll) chloride hexahydrate (160 mg, 0.4 mmol) as starting material.
- the complex was prepared from H3macita-3HCI-H 2 0 ( 150 mg , 0.3 mmol) and holmium(lll) chloride hexahydrate (164 mg, 0.4 mmol) by following the protocol for the preparation of the lutetium complex Na3[Lu3(H-3macita)2].
- the complex was prepared according to the protocol for the lutetium complex Na3[Lu3(H. 3macita)2] using h macita-SHCI I- O (150 mg, 0.3 mmol) and erbium(lll) chloride hexahydrate (165 mg, 0.4 mmol) as starting material.
- H 3 macita-3HCI-H 2 0 400 mg, 0.8 mmol
- ytterbium(lll) chloride hexahydrate 398 mg, 1.0 mmol
- Sodium hydroxide (1 M) was added to adjust the pH to ⁇ 8 and the clear solution was heated to reflux for 3 h .
- the solution was desalted via ultra filtration (cellulose acetate membrane, lowest NMWL 500 g/mol , Millipore). The filtrate was evaporated to dryness and the white solid dried in vacuo.
- H 3 tacitp-3HCI-3H 2 0 500 mg, 0.9 mmol was dissolved in water (20 ml_). 1 M sodium hydroxide (8.1 ml_, 8.1 mmol) as well as hafnium(IV) chloride (489 mg , 1 .5 mmol) dissolved in water (5 mL) were successively added. The pH was adjusted to ⁇ 3 (1 M hydrochloric acid) and the suspension was heated to reflux for 3 days. The solids were filtered off and the filtrate was passed through a mixed bed ionic exchange column (Amberlite MB-61 13) which was eluted with water (500 mL). The eluate was lyophilized to get the product as a white solid.
- Theta range for data collection 1 .55 to 33.36°.
- U(eq) is defined as one third of the trace of the orthogonalized U'J tensor.
- Figure 5 shows the crystal structure
- H 3 tacitp-3HCI-3H 2 0 (100 mg, 0.2 mmol) was dissolved in water (10 mL) and 1 .6 eq of lutetium(lll) chloride hexahydrate (1 18 mg dissolved in water, 0.3 mmol) was added. The pH was adjusted to ⁇ 8 (1 M sodium hydroxide). The suspension was stirred at 80 °C for 1 h and filtered afterwards. The solution was desalted via ultra filtration (cellulose acetate membrane, lowest NMWL 500 g/mol, Millipore). The filtrate was evaporated to dryness and the white solid dried in vacuo.
- the complex was prepared according to the protocol for the lutetium complex Na 3 [Lu 3 (H. 3 tacitp) 2 ] u si ng H 3 tacitp-3HCI-3H 2 0 (100 mg, 0.2 mmol) and holmium(lll) chloride hexahydrate (109 mg, 0.3 mmol) as starting material. Yield : 65 mg (49 %) Na 3 [Ho 3 (H. 3 tacitp) 2 ]-8H 2 0. Single crystals of the composition D 3 - K 3 [Ho 3 (H- 3 tacitp) 2 ]-14.5H 2 0 were obtained by slow evaporation of an aqueous solution of the complex (potassium hydroxide used in the synthesis).
- U(eq) is defined as one third of the trace of the orthogonalized U'J tensor.
- Figure 6 shows the crystal structure
- H 3 tacitp-3HCI-3H 2 0 (100 mg, 0.2 mmol) was dissolved in water (10 mL) and 1.6 eq of erbium(lll) chloride hexahydrate (110 mg, 0.3 mmol) dissolved in water (10 mL) was added. The pH was adjusted to ⁇ 8 (1 M sodium hydroxide). The suspension was stirred at 80 °C for 1 h and filtered afterwards. The solvent was removed and the residue was treated with hot ethanol (50 mL). The insoluble salts were filtered off, the filtrate evaporated to dryness and the rose solid dried in vacuo. Yield: 58 mg (40 %) Na 3 [Er3(H. 3 tacitp) 2 ]-15H 2 0.
- the complex was prepared according to the protocol for the erbium complex Na 3 [Er 3 (H. 3 tacitp) 2 ] u s i n g H 3 tacitp-3HCI-3H 2 0 (100 mg, 0.2 mmol) and ytterbium(lll) chloride hexahydrate (1 12 mg, 0.3 mmol) as starting material.
- H 3 macitp-3HCI-4.5H 2 0 (1 .3 g, 2.1 mmol) was dissolved in water ( 100 mL) and treated with sodium hydroxide (18.7 mL of a 1 M solution, 18.7 mmol).
- Hafnium (IV) tetrachloride (1 .1 g, 3.4 mmol) dissolved in a small amount of water was added and the pH was adjusted to ⁇ 3 (adjusted with 1 M hydrochloric acid).
- the solution was heated to reflux for 3 days.
- the white solid was filtered off and the filtrate was passed through a mixed bed ionic exchange column (Amberlite MB-61 13) which was eluted with water.
- the eluate was lyophilized to get the 1 .23 g raw product as a white solid which was purified by preparative HPLC.
- the complex was prepared according to the protocol for the erbium complex Na 3 [Er 3 (H. 3 tacitp) 2 ] using H 3 macitp-3HCI-4.5H 2 0 (100 mg, 0.2 mmol) and lutetium(lll) chloride hexahydrate (100 mg, 0.3 mmol) as starting material.
- Theta range for data collection 1 .64 to 28.37°.
- Figure 7 shows the crystal structure
- the complex was prepared from H3macitp-3HCI-4.5H20 ( 1 00 mg , 0.2 m mol ) a nd gadolinium(lll) chloride hexahydrate (95 mg, 0.3 mmol) by following the protocol for the preparation of the erbium complex Na3[Er3(H-3tacitp)2].
- the complex was prepared according to the protocol for the erbium complex a3[Ers (H-3tacitp) 2 ] using H3macitp-3HCI-4.5H 2 0 (100 mg, 0.2 mmol) and holmium(lll) chloride hexahydrate (97 mg, 0.3 mmol) as starting material. Yield: 72 mg (54 %) Na 3 [Ho3(H-3macitp)2]-13H 2 0.
- the complex was prepared from H 3 macitp-3HCI-4.5H20 ( 1 00 mg , 0.2 m mol ) a nd erbium(lll) chloride hexahydrate (98 mg, 0.3 mmol) by following the protocol for the preparation of the erbium complex Na3[Er3(H-3tacitp)2].
- Atomic coordinates ( x 10 ⁇ ) and equivalent isotropic displacement parameters (A3 ⁇ 4 U(eq) is defined as one third of the trace of the orthogonalized U'J tensor.
- the stability of bis azainositol heavy metal complexes was determined in aqueous, buffered solution at pH 7.4.
- the solution containing 5 mmol/L of the compound in a tightly sealed vessel was heated to 121 °C for 45 min in a steam autoclave.
- the metal concentration of the solution was determined by ICP-OES before and after heat treatment.
- the integrity of the compound was determined by HPLC analysis before and after heat treatment. Absolute stability was calculated as the ratio of the peak area of the compound after and before the heat treatment multiplied with the ratio of the metal concentration of the solution after and before heat treatment.
- HPLC system HPLC system:
- Solvent A1 1 m hexylamine + 1 mM bis-tris pH 6.5
- Solvent A2 0,5 mM tetrabutylammonium phosphate pH 6
- Solvent B methanol, HPLC grade
- Detector D1 element specific detection by ICP-OES running at the most sensitive emission wavelength of the respective complexed metal.
- Detector D2 element specific detection by ICP-MS running at the most abundant isotope of the respective complexed metal.
- X-ray computed tomography To demonstrate th e efficacy of the X-ray d iag nostic agent a preclinical animal investigation was performed using X-ray computed tomography (CT). The study was performed on a clinical CT unit (Sensation 64, Siemens Medical Solutions, Er Weg, Germany) with an anaesthetized rat. The compound described in example 2 was used as X-ray diagnostic agents in order to perform contrast enhanced CT imaging. The study was performed on a healthy Han-Wistar rat. Initial anaesthesia was induced by inhalation of 4% Isoflurane (Baxter Deutschland GmbH, UnterschleiBheim, Germany) and maintained by 1 .5% Isoflurane.
- the rat was placed within a tissue equivalent phantom (QRM, Mohrendorf, Germany) that mimics the human abdomen in respect of X-ray absorption. Thus comparable conditions to a situation in humans were ensured regarding X-ray scattering and X-ray beam hardening.
- An X-ray projection image (topogram) was acquired to adjust the measurement range to the thoracal region of the animal.
- the signal change caused by the diagnostic agent is shown in Figure 1 .
- the signal time course in the heart and major blood vessels are visualized on representative images:
- the native baseline image showed an intrinsically high CT signal of the skeleton a maxim m sig nal for tissue and low signal for the lu ng .
- the signal-time course in the left heart chamber was quantified by a region of interest analysis. Therefore an identical circular region covering the left heart chamber was drawn on the images.
- the mean signal value for each time point was normalized to the baseline image resulting in a signal-change time curve (Fig.2).
- the high CT-signal during the passage of the diagnostic agent i.e. between 3-6s on Fig.2) demonstrates the highly effective X-ray attenuation of the X-ray diagnostic agent.
- the Hafnium concentration in all specimen was determined after digestion in oxidizing solution (nitric acid and hydrogen peroxide) at elevated pressure and temperature. The measurement of Hafnium was performed by ICP-MS.
- the Hafnium concentration in all blood samples was determined after digestion in oxidizing sol ution (nitric acid and hyd rogen peroxide) at elevated pressu re and temperature. The measurement of Hafnium was performed by ICP-MS.
- the pharmacokinetic parameters were obtained for each animal by fitting the blood concentrations to a 3-compartment model, using the software WinNonlin.
- the third compartment contributed less than 4% to the Area-under-the-curve and was therefore neglected.
- the blood half live was 22.6 ⁇ 3.1 min, the volume of distribution was 0.31 ⁇ 0.01 l/kg and total plasma clearance was 10 ⁇ 0.6 mL/min/kg.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201380025924.0A CN104321082A (en) | 2012-05-18 | 2013-04-25 | Bis azainositol heavy metal complexes for X-ray imaging |
EP13720854.2A EP2849804A1 (en) | 2012-05-18 | 2013-04-25 | Bis azainositol heavy metal complexes for x-ray imaging |
JP2015511976A JP2015517507A (en) | 2012-05-18 | 2013-04-25 | Bisazainositol heavy metal complexes for X-ray imaging |
CA2873652A CA2873652A1 (en) | 2012-05-18 | 2013-04-25 | Bis azainositol heavy metal complexes for x-ray imaging |
US14/402,050 US20150132229A1 (en) | 2012-05-18 | 2013-04-25 | Bis azainositol heavy metal complexes for x-ray imaging |
HK15106097.2A HK1205465A1 (en) | 2012-05-18 | 2015-06-26 | Bis azainositol heavy metal complexes for -ray imaging |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12075048 | 2012-05-18 | ||
EP12075048.4 | 2012-05-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013171048A1 true WO2013171048A1 (en) | 2013-11-21 |
Family
ID=48325633
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2013/058590 WO2013171048A1 (en) | 2012-05-18 | 2013-04-25 | Bis azainositol heavy metal complexes for x-ray imaging |
Country Status (7)
Country | Link |
---|---|
US (1) | US20150132229A1 (en) |
EP (1) | EP2849804A1 (en) |
JP (1) | JP2015517507A (en) |
CN (1) | CN104321082A (en) |
CA (1) | CA2873652A1 (en) |
HK (1) | HK1205465A1 (en) |
WO (1) | WO2013171048A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2796152A1 (en) * | 2013-04-25 | 2014-10-29 | Bayer Pharma Aktiengesellschaft | Unsymmetrical Bis Azainositol Hafnium Complexes for X-Ray Imaging |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0190676A1 (en) | 1985-02-02 | 1986-08-13 | Laboratorien Hausmann AG | Cis-1,3,5-triamino 2,4,6-cyclohexanetriol derivatives, their use, process for their preparation and pharmaceutical preparations containing them |
WO1990008138A1 (en) | 1989-01-13 | 1990-07-26 | Nycomed As | Heterocyclic chelating agents |
WO1991010454A1 (en) | 1990-01-09 | 1991-07-25 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Transition metal complexes for magnetic resonance diagnosis |
DE4028139A1 (en) | 1990-09-05 | 1992-03-12 | Hausmann Ag Labor | USE OF THE COMPLEX RADIOACTIVE METALLIONS WITH ALL-CIS-1,3,5-TRIAMINO-2,4,6-CYCLOHEXANTRIOL AND ITS DERIVATIVES FOR X-RAY DIAGNOSTIC PURPOSES AND IN TUMOR THERAPY AND THE PRODUCTION OF MEDICINE AND FUTURE AND FUTURE AND FURNITURE AND FUTURE |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5672335A (en) * | 1994-11-30 | 1997-09-30 | Schering Aktiengesellschaft | Use of metal complexes as liver and gallbladder X-ray diagnostic agents |
-
2013
- 2013-04-25 CN CN201380025924.0A patent/CN104321082A/en active Pending
- 2013-04-25 US US14/402,050 patent/US20150132229A1/en not_active Abandoned
- 2013-04-25 EP EP13720854.2A patent/EP2849804A1/en not_active Withdrawn
- 2013-04-25 CA CA2873652A patent/CA2873652A1/en not_active Abandoned
- 2013-04-25 JP JP2015511976A patent/JP2015517507A/en active Pending
- 2013-04-25 WO PCT/EP2013/058590 patent/WO2013171048A1/en active Application Filing
-
2015
- 2015-06-26 HK HK15106097.2A patent/HK1205465A1/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0190676A1 (en) | 1985-02-02 | 1986-08-13 | Laboratorien Hausmann AG | Cis-1,3,5-triamino 2,4,6-cyclohexanetriol derivatives, their use, process for their preparation and pharmaceutical preparations containing them |
WO1990008138A1 (en) | 1989-01-13 | 1990-07-26 | Nycomed As | Heterocyclic chelating agents |
WO1991010454A1 (en) | 1990-01-09 | 1991-07-25 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Transition metal complexes for magnetic resonance diagnosis |
DE4028139A1 (en) | 1990-09-05 | 1992-03-12 | Hausmann Ag Labor | USE OF THE COMPLEX RADIOACTIVE METALLIONS WITH ALL-CIS-1,3,5-TRIAMINO-2,4,6-CYCLOHEXANTRIOL AND ITS DERIVATIVES FOR X-RAY DIAGNOSTIC PURPOSES AND IN TUMOR THERAPY AND THE PRODUCTION OF MEDICINE AND FUTURE AND FUTURE AND FURNITURE AND FUTURE |
WO1992004056A1 (en) | 1990-09-05 | 1992-03-19 | Laboratorien Hausmann Ag | USE OF RADIOACTIVE METAL ION COMPLEXES WITH all-cis-1,3,5-TRIAMINO-2,4,6-CYCLOHEXANTRIOL AND THEIR DERIVATES FOR X-RAY DIAGNOSIS AND IN TUMOR THERAPY AS WELL AS FOR PRODUCING X-RAY DIAGNOSTIC AND TUMOR THERAPY AGENTS |
Non-Patent Citations (20)
Title |
---|
A. EGLI, DISSERTATION, 1994 |
BARTHOLOMÄ, M.; GISBRECHT, S.; STUCKY, S.; NEIS, C.; MORGENSTERN, B.; HEGETSCHWEILER, K., CHEM. EUR. J., vol. 16, 2010, pages 3326 |
CHAPON ET AL., J. ALL. COMP., vol. 323-324, 2001, pages 128 |
CHEM. SOC. REV., vol. 28, 1999, pages 239 |
D. P. TAYLOR; G. R. CHOPPIN, INORG. CHIM. ACTA, vol. 360, 2007, pages 3712 |
G. WELTI, DISSERTATION, 1998 |
GHISLETTA, M.; JALETT, H.-P.; GERFIN, T.; GRAMLICH, V.; HEGETSCHWEILER, K., HELV. CHIM. ACTA, vol. 75, 1992, pages 2233 |
GREGOR WELTI: "1,3,5-Triamino-1,3,5-tridesoxy-cis-inosit-Derivate fuer die Radioimmunotherapie und zur Behandlung der Thalassaemie", DISSERTATION, NATURWISS. ETH ZÜRICH, ZÜRICH, CH, no. Diss. Nr. 12613, 1998, pages 1 - 84, XP008154572 * |
HEGETSCHWEILER ET AL., CHEM. SOC. REV., vol. 28, 1999, pages 239 |
INORG. CHEM., vol. 32, 1993, pages 2699 |
INORG. CHEM., vol. 36, 1997, pages 4121 |
INORG. CHEM., vol. 37, 1998, pages 6698 |
JANON E., A. AM. J. ROENTGEN, vol. 152, 1989, pages 1348 |
KASPAR HEGETSCHWEILER ET AL: "1,3,5-Triamino-1,3,5-trideoxy-cis-inositol, a new ligand with a remarkable versatility for metal ions. 4. Preparation, characterization, and x-ray structure of the trinuclear lead(II) and bismuth(III) complexes", INORGANIC CHEMISTRY, vol. 32, no. 12, 1 June 1993 (1993-06-01), pages 2699 - 2704, XP055041348, ISSN: 0020-1669, DOI: 10.1021/ic00064a020 * |
ROMAN HEDINGER ET AL: "Trinuclear Lanthanoid Complexes of 1,3,5-Triamino- 1,3,5-trideoxy-cis-inositol with a Unique, Sandwich-Type Cage Structure", INORGANIC CHEMISTRY, vol. 37, no. 26, 1 January 1998 (1998-01-01), pages 6698 - 6705, XP008145616, ISSN: 0020-1669, [retrieved on 19981101], DOI: 10.1021/IC980685S * |
SHELDRICK, G. M.: "Program for Crystal Structure Refinement", SHELXL-97, 1997 |
SHELDRICK, G. M.: "Program for Crystal Structure Solution", SHELXS-97, 1990 |
SPEK, A. L., ACTA. CRYST., vol. D65, 2009, pages 148 |
SPEK, A. L.: "A Multipurpose Crystallographic Tool", PLATON, 2011 |
UNGER E.; GUTIERREZ F., INVEST. RADIOL., vol. 21, 1986, pages 802 |
Also Published As
Publication number | Publication date |
---|---|
CA2873652A1 (en) | 2013-11-21 |
US20150132229A1 (en) | 2015-05-14 |
JP2015517507A (en) | 2015-06-22 |
HK1205465A1 (en) | 2015-12-18 |
EP2849804A1 (en) | 2015-03-25 |
CN104321082A (en) | 2015-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW319763B (en) | ||
Brücher | Kinetic stabilities of gadolinium (III) chelates used as MRI contrast agents | |
JP2968367B2 (en) | 1,4,7,10-Tetraazacyclododecane-butyltriol, its gadolinium complex, pharmaceuticals and diagnostics containing it, method for producing the compound and method for producing pharmaceuticals | |
JP2667666B2 (en) | Paramagnetic polyvalent metal salt of poly- (acid-alkylene-amino) -alkane | |
JP4689775B2 (en) | Low toxicity paramagnetic metal chelate complexes | |
CN108368067B (en) | Dimeric contrast agents | |
DE69032374T2 (en) | MULTI-TEED METAL CHELATING COMPOUNDS | |
JPH082855B2 (en) | New magnetic resonance contrast agent | |
JPH03209389A (en) | Physiologically acceptable complex salt | |
AU2017375728B2 (en) | Dimeric contrast agents | |
DE69417754T2 (en) | CHELATE AS A CONTRAST-IMPROVING AGENT | |
WO1992004919A1 (en) | Novel magnetic resonance imaging agents | |
DE69226022T2 (en) | HYDROXAMATE AND HYDRAZIDE DERIVATIVES OF POLYAMINES AND THEIR MEDICAL USE AS CHELATIVE ACTIVE SUBSTANCES | |
AU647188B2 (en) | Magnetic resonance imaging agent | |
EP0513000B1 (en) | Mri image enhancement of bone and related tissue using complexes of paramagnetic cations and polyphosphonate ligands | |
EP0755385A1 (en) | Chelant compounds | |
WO2013171048A1 (en) | Bis azainositol heavy metal complexes for x-ray imaging | |
EP1742926B1 (en) | Macrocycle-substituted trimer halogen-benzol derivatives | |
NZ236267A (en) | 10-(2'-hydroxy-3'-polyoxaalkyl)-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane | |
WO2005115997A1 (en) | Trimeric macrocyclic substituted aminoisophthalate halophenyl derivatives | |
US20160060209A1 (en) | Bis azainositol hafnium complexes for x-ray imaging | |
WO2010029947A1 (en) | Contrast medium composition and process for producing same | |
TW201524987A (en) | Bis azainositol hafnium complexes for X-ray imaging | |
KR101239130B1 (en) | Magnetic resonance imaging contrast agent and a process for the preparation thereof | |
WO2024052573A1 (en) | Combinations of contrast agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13720854 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2873652 Country of ref document: CA Ref document number: 2015511976 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013720854 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14402050 Country of ref document: US |